DK382989D0 - Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf - Google Patents

Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf

Info

Publication number
DK382989D0
DK382989D0 DK382989A DK382989A DK382989D0 DK 382989 D0 DK382989 D0 DK 382989D0 DK 382989 A DK382989 A DK 382989A DK 382989 A DK382989 A DK 382989A DK 382989 D0 DK382989 D0 DK 382989D0
Authority
DK
Denmark
Prior art keywords
cytotoxic
antibodies
procedures
producing
bonded
Prior art date
Application number
DK382989A
Other languages
English (en)
Other versions
DK382989A (da
Inventor
George Joseph Cullinan
Bennett Coleman Laguzza
William Leonard Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK382989D0 publication Critical patent/DK382989D0/da
Publication of DK382989A publication Critical patent/DK382989A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK382989A 1988-08-08 1989-08-04 Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf DK382989A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/230,084 US5006652A (en) 1988-08-08 1988-08-08 Intermediates for antibody-vinca drug conjugates

Publications (2)

Publication Number Publication Date
DK382989D0 true DK382989D0 (da) 1989-08-04
DK382989A DK382989A (da) 1990-02-09

Family

ID=22863896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK382989A DK382989A (da) 1988-08-08 1989-08-04 Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf

Country Status (15)

Country Link
US (1) US5006652A (da)
EP (1) EP0354728A3 (da)
JP (1) JPH02131499A (da)
KR (1) KR900002804A (da)
CN (1) CN1040205A (da)
AR (1) AR245368A1 (da)
AU (1) AU619329B2 (da)
DK (1) DK382989A (da)
HU (1) HU206377B (da)
IL (1) IL91182A0 (da)
MX (1) MX164971B (da)
NZ (1) NZ230200A (da)
PH (1) PH27351A (da)
PT (1) PT91372A (da)
ZA (1) ZA895908B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
ES2049656B1 (es) * 1992-10-08 1994-11-16 Lilly Co Eli Grupos de conjugados de farmacos con anticuerpos.
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
AU2002217980A1 (en) 2000-12-01 2002-06-11 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
JP4814520B2 (ja) * 2002-05-15 2011-11-16 エンドサイト,インコーポレイテッド ビタミン−マイトマイシン結合体
PT1592457E (pt) 2003-01-27 2012-11-02 Endocyte Inc Conjugados de entrega farmacológica de ligação a recetores de vitaminas
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト,インコーポレイテッド プテロイン酸およびその結合体の合成と精製
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
JP5475992B2 (ja) * 2005-08-19 2014-04-16 エンドサイト,インコーポレイテッド 多剤リガンド結合体
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ580132A (en) * 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
AU2008268432B2 (en) * 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101909441B (zh) 2007-10-25 2015-05-13 恩多塞特公司 微管蛋白抑制剂及其制备方法
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
KR20150070318A (ko) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
PT2968440T (pt) 2013-03-15 2019-07-31 Zymeworks Inc Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos
PL3086815T3 (pl) 2013-12-27 2022-06-13 Zymeworks Inc. Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe
CN113416229A (zh) 2014-09-17 2021-09-21 酵活有限公司 细胞毒性和抗有丝分裂化合物、及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
GR79899B (da) * 1983-03-30 1984-10-31 Lilly Industries Ltd
HUT34212A (en) * 1983-04-29 1985-02-28 Omnichem Sa Process for the production of new vindblastin conjugates
LU86157A1 (fr) * 1985-11-12 1987-06-26 Omnichem Sa Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
PT89504A (pt) * 1988-01-27 1989-10-04 Lilly Co Eli Processo para a preparacao de conjugados de anticorpos com hidrazidas de vinca

Also Published As

Publication number Publication date
DK382989A (da) 1990-02-09
EP0354728A3 (en) 1991-04-10
EP0354728A2 (en) 1990-02-14
HUT50488A (en) 1990-02-28
US5006652A (en) 1991-04-09
ZA895908B (en) 1991-04-24
CN1040205A (zh) 1990-03-07
HU206377B (en) 1992-10-28
AU619329B2 (en) 1992-01-23
IL91182A0 (en) 1990-03-19
AR245368A1 (es) 1994-01-31
AU3933989A (en) 1990-02-08
KR900002804A (ko) 1990-03-23
PH27351A (en) 1993-06-21
MX164971B (es) 1992-10-09
NZ230200A (en) 1991-11-26
PT91372A (pt) 1990-03-08
JPH02131499A (ja) 1990-05-21

Similar Documents

Publication Publication Date Title
DK382989A (da) Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf
DK382889D0 (da) Konjugater af antistoffer og cytotoxiske methotrexat-forbindelser og fremgangsmaade til fremstilling af saadanne konjugater
DE3584559D1 (de) Therapeutische antikoerpermittelkonjugate.
NO893464D0 (no) Fremgangsmaate for aa anbringe et legeme av formminnemateriale i et hulrom.
DK194589D0 (da) Partikelformede vaskemidler og fremgangsmaade til fremstilling deraf
DK251188D0 (da) Goedningsmiddel og fremgangsmaade til fremstilling deraf
DK665187A (da) Immunoglobulin-konjugater og fremgangsmaade til fremstilling heraf
DK260687A (da) Immunoglobulin-konjugater og fremgangsmaade til fremstilling deraf
EP0359063A3 (en) Antibody having high affinity to hapten as antigen and immunogen for obtaining the same
DK556689A (da) Antistof-konjugater, fremgangsmaade til fremstilling heraf og farmaceutiske midler indeholdende disse
DK397788A (da) Polyarylalkan-oligomer-praeparater og fremgangsmaade til fremstilling deraf
DK32989D0 (da) Immunoglobulin-konjugater og fremgangsmaade til fremstilling deraf
DK131588A (da) Immunoglobulinkonjugater
AU590731B2 (en) Estriol-3-sulfate protein conjugates and antibodies thereto
DK129689D0 (da) Ifosfamid-mesna-lyofilisat og fremgangsmaade til fremstilling deraf
AU5217890A (en) Monoclonal antibodies in vaccine formulations
DK240289D0 (da) Cellulose-kompositmateriale og fremgangsmaade til fremstilling deraf
ATE68974T1 (de) Therapeutische antikoerpermittelkonjugate.
DK287288A (da) Polypeptid og fremgangmaade til fremstilling deraf
DK319188A (da) Glycerolacetalaminoacylat og fremgangsmaade til fremstilling deraf
KR900000142U (ko) 목걸이 결합구
GB8705550D0 (en) Monoclonal antibodies to urokinase
DK110787D0 (da) Konjugater
DK594488D0 (da) Plantegummimateriale og fremgangsmaade til fremstilling af samme
IE861508L (en) Antibody conjugates

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment